中国构建 · 海外临床
全球交易布局
Built in China, Clinically Advanced Globally,
Positioned for Worldwide Deals
高效打造新模态管线，满足全球新药需求 Efficiently incubating new-modality pipelines to meet global medicine demand
智和领（Intelli-Link Therapeutics）是一家立足中国、面向全球的新模态药物管线孵化平台。公司基于自主工程化平台，构建了自免双抗、代谢减脂及 Next-Gen 双特异 ADC 三大高价值资产矩阵，依托全流程闭环能力将 PCC 到 FIH 阶段的转化周期压缩至 12–14 个月，高效兑现全球交易与临床价值。 Intelli-Link Therapeutics is a China-based, globally oriented new-modality pipeline incubation platform. Built on proprietary engineering platforms, we have assembled three high-value asset matrices — autoimmune bispecifics, metabolic fat-loss antibodies and Next-Gen bispecific ADCs — and, powered by full-cycle closed-loop capability, compress the PCC-to-FIH translation window to 12–14 months, efficiently delivering global transaction and clinical value.
自身免疫Autoimmune
3 条差异化双特异性抗体管线，聚焦哮喘、特应性皮炎、炎症性肠病Three differentiated bispecific antibody programs focused on asthma, atopic dermatitis and inflammatory bowel disease
代谢｜体成分管理Metabolism | Body Composition
ActRII 双资产组合，解决 GLP-1 减重伴随的肌肉流失难题A dual-asset ActRII portfolio tackling muscle loss accompanying GLP-1 weight loss
肿瘤｜双特异 ADCOncology | Bispecific ADC
3 条双特异 ADC 管线，覆盖肺癌、前列腺癌及多种上皮来源实体瘤Three bispecific ADC programs covering lung, prostate and multiple epithelial-derived solid tumors
查看全部管线资产，或直接与我们的商务拓展团队取得联系。Browse all pipeline assets, or reach our business development team directly.
查看管线全览View Full Pipeline 联系我们Contact Us从早期发现到全球交易的一体化转化平台An Integrated Translation Platform: From Early Discovery to Global Deals
我们是谁Who We Are
智和领是一家立足中国、面向全球的新模态药物管线孵化平台，专注于将前沿抗体工程与 AI 辅助设计相结合，打造具有临床差异化与全球交易价值的新模态药物资产。公司聚焦自身免疫、代谢（体成分管理）与肿瘤三大治疗领域，目前已布局 8 项核心资产。 Intelli-Link is a China-based, globally oriented new-modality pipeline incubation platform, combining frontier antibody engineering with AI-assisted design to build new-modality assets with clinical differentiation and global transaction value. We focus on three therapeutic areas — autoimmune, metabolism (body composition) and oncology — with 8 core assets in place.
我们的模式Our Model
「早期发现 + 工程化落地 + 加速临床验证 + 共建全球布局」——智和领依托战略股东领康时代（CDMO，覆盖 CMC、IND 申报至商业化生产）及战略合作单位百试达（Syneos 子公司，覆盖中美双报及多中心临床执行），实现从概念候选化合物（PCC）到首次人体试验（FIH）阶段的高效转化，管线转化周期可控制在 12–14 个月内。 "Early discovery + engineered translation + accelerated clinical validation + global co-build." Backed by strategic shareholder Llinkera CDMO covering CMC, IND filing through commercial manufacturing, and strategic partner Baishida (a Syneos Health subsidiary) covering China + US dual filings and multi-site clinical execution, Intelli-Link drives efficient conversion from PCC to FIH within 12–14 months.
核心优势Core Advantages
工程化能力Engineering Capability
基于纳米抗体（VHH）与多特异性抗体设计的自主工程平台，在保留疗效的同时显著降低分子量、提升组织穿透力并优化生产成本A proprietary VHH nanobody and multispecific antibody engineering platform that markedly reduces molecular weight, improves tissue penetration and optimizes manufacturing cost while preserving efficacy
端到端转化End-to-End Translation
战略股东与合作方覆盖 CMC 生产、IND 申报与中美双报临床执行，PCC 到 FIH 转化周期可控制在 12–14 个月内Strategic shareholders and partners cover CMC manufacturing, IND filings and China + US dual clinical execution, keeping the PCC-to-FIH cycle within 12–14 months
靶点选择逻辑Target Selection Logic
所有管线均选取已获临床验证的靶点组合进行差异化再设计，兼顾成药确定性与专利 / 机制层面的差异化空间Every pipeline is a differentiated redesign of clinically validated target combinations, balancing developability certainty with patent and mechanistic differentiation
全球化布局Global Positioning
中国构建、海外临床、全球交易布局，服务全球范围内的战略防御型 MNC、ADC 赛道竞争者及国内出海转型药企Built in China, advanced in global clinics, structured for worldwide transactions — serving strategically defensive MNCs, ADC-space competitors and China-based innovators going global
转化路径Translation Path
早期发现Early Discovery
基于已验证靶点的差异化组合设计与抗体工程优化Differentiated combination design and antibody engineering built on validated targets
工程化落地Engineered Translation
PCC 确认、动物药效验证，CMC 同步准备PCC confirmation and animal PD validation, with CMC prepared in parallel
加速临床转化Accelerated Clinical Translation
IND 申报与中美双报临床执行，12–14 个月抵达 FIHIND filings and China + US dual clinical execution, reaching FIH in 12–14 months
三大技术平台，支撑差异化管线设计Three Technology Platforms Powering Differentiated Pipeline Design
从靶点组合策略到分子构型工程，我们的平台贯穿自免、代谢与肿瘤三大领域。From target-combination strategy to molecular format engineering, our platforms span autoimmune, metabolic and oncology.
双特异性抗体设计平台Bispecific Antibody Design Platform自身免疫Autoimmune
聚焦「上下游通路协同阻断」的设计逻辑：当单一靶点的上游或下游阻断存在疗效天花板时，通过双特异性抗体同时覆盖互补通路，突破现有生物制剂的应答瓶颈。Built on a "coordinated upstream-downstream blockade" design logic: when single-target blockade hits an efficacy ceiling, the bispecific format covers complementary pathways at once, breaking through the response limits of current biologics.
- 分子构型：2+2 四价双抗设计，兼顾亲和力与空间协同效应（Avidity）Format: 2+2 tetravalent design balancing affinity with avidity effects
- 靶点组合策略：优先选择均已获得单靶点临床验证的通路进行组合，降低机制验证风险Target strategy: combining pathways each already clinically validated as single targets, de-risking mechanism validation
ActRII 代谢通路平台ActRII Metabolic Pathway Platform体成分管理Body Composition
面向 GLP-1 时代的「质量减重」需求，围绕 Activin 受体 II 型（ActRII）通路布局选择性与双受体两条工程路线，通过受体亲和力偏向性设计，在保留肌肉的同时实现精准减脂。Addressing "quality weight loss" in the GLP-1 era, the platform pursues selective and dual-receptor engineering routes along the ActRII pathway, using affinity-biased receptor design to shed fat precisely while preserving muscle.
- 工程路线互补：选择性阻断 ActRIIA 或双受体协同阻断，覆盖不同疗效与安全性定位需求Complementary routes: selective ActRIIA blockade or dual-receptor blockade for different efficacy/safety profiles
- 临床定位：与 GLP-1 受体激动剂联用，形成「控食欲、快速降体重」+「保肌肉、纯减脂」的协同组合Clinical positioning: combine with GLP-1 RAs — "appetite control, rapid weight-down" plus "muscle-sparing, pure fat loss"
双 VHH 纳米抗体 ADC 平台Dual-VHH Nanobody ADC Platform肿瘤Oncology
面向实体瘤，以单域纳米抗体（VHH）为核心设计新一代双特异性 ADC，并可根据靶点结合结构域的可得性灵活选用双 VHH 串联，或 VHH + 全长单抗结合结构域的非对称构型：双 VHH 串联构型相较传统 IgG 双抗 ADC 分子量可降低约 60–70%，具备更强的组织穿透力与更均一的定点偶联能力；非对称构型则可在复用已验证单抗结合活性的同时，保留 VHH 一侧的工程化灵活性与成本优势。Designing next-generation bispecific ADCs around single-domain nanobodies (VHH), with the flexibility to choose tandem dual-VHH or an asymmetric VHH + full-length mAb binding-domain format based on target-domain availability: the tandem dual-VHH format cuts molecular weight ~60–70% versus conventional IgG bispecific ADCs with stronger tissue penetration and more uniform site conjugation, while the asymmetric format reuses validated mAb binding activity and retains VHH-side engineering flexibility and cost advantages.
- 结构优势：VHH 凸环结构（CDR3）可深入 GPCR 等复杂靶点的狭窄结合口袋，提升结合与内化效率Structural edge: the extended CDR3 loop reaches narrow binding pockets of complex targets such as GPCRs, improving binding and internalization
- 架构灵活性：双 VHH 串联适合追求极致小分子量与穿透力的场景；VHH + 全长单抗的非对称构型适合复用已验证结合活性、加快分子定型的场景Architecture flexibility: tandem dual-VHH for minimal size and maximal penetration; the asymmetric VHH + full-length mAb format for reusing validated binding activity and faster molecular lock-down
- CMC 优势：VHH 一侧结构单一对称，天然适合定点偶联，有助于提升 DAR 均一性、降低生产成本CMC edge: the VHH side’s uniform symmetric architecture inherently suits site conjugation, improving DAR homogeneity and lowering cost
为什么「双 VHH」是结构性差异Why Dual-VHH Is a Structural Differentiator
传统 IgG 双抗 ADC 分子量大、结构复杂；双 VHH 串联构型体积仅为传统 IgG 抗体的 1/4，在分子量、组织穿透性与生产成本上具备结构性优势；平台亦可采用 VHH + 全长单抗的非对称构型，复用已验证抗体结合活性。Conventional IgG bispecific ADCs are large and architecturally complex. The tandem dual-VHH format is roughly one-quarter the size of a conventional IgG — a structural advantage in molecular weight, penetration and cost — while the platform can also deploy an asymmetric VHH + full-length mAb format to reuse validated binding activity.
8 项核心资产，面向全球开放合作8 Core Assets, Open for Global Partnership
所有管线均基于临床已验证的靶点组合，具备清晰的 First-in-class 或 Fast-follower + 差异化定位。All pipelines are built on clinically validated target combinations with clear First-in-class or fast-follower-plus-differentiation positioning.
点击任一资产行，查看适应症方向、科学亮点与合作状态；如需完整数据包，请前往合作伙伴页面提交需求。靶点全称、分子设计与体内外数据可在 NDA 框架下提供。Click any asset row to view indication focus, scientific highlights and partnering status. For full data packages, submit your request on the Partnering page. Target identities, molecular designs and in vivo/in vitro data are available under NDA.
与智和领共建全球新模态管线Build Global New-Modality Pipelines with Intelli-Link
灵活的合作结构，覆盖区域授权、联合开发与全球战略共建。Flexible deal structures spanning regional licensing, co-development and global strategic co-building.
大中华区独家区域授权Greater China Exclusive Regional License
面向国内药企优先开放，覆盖大中华区独家权益Prioritized for domestic pharma, covering exclusive Greater China rights
限定大中华区联合共同开发Greater China Co-Development
与合作方共担开发成本，共享大中华区商业化权益Shared development costs and shared Greater China commercialization rights
全球权益共建 / 海外 License-outGlobal Co-Build / Ex-China License-out
面向全球战略药企开放，涵盖 License-out、里程碑付款及销售分成等结构Open to global strategic pharma: license-out structures with milestone payments and royalties
典型合作路径Typical Deal Structures
License-out / 全球或区域授权License-out / Global or Regional
首付款 + 开发里程碑 + 销售里程碑 + 销售分成Upfront + development milestones + sales milestones + royalties
联合开发Co-Development
共担临床开发成本，共享商业化权益Shared clinical development costs, shared commercialization rights
战略共建（PCC → IND → Ph I）Strategic Co-Build (PCC → IND → Ph I)
智和领负责早期工程化与临床转化，合作方获得后续权益或股权抵扣Intelli-Link owns early engineering and clinical translation; partners receive follow-on rights or equity offset
合作流程Engagement Process
初步接触Initial Contact
提交合作意向表单，说明关注领域与合作诉求Submit an intent form outlining your area of interest and partnership goals
资料交换Material Exchange
签署保密协议后，获取非保密数据摘要与完整数据室（Data Room）访问权限After NDA execution, receive the non-confidential teaser and full Data Room access
尽调与谈判Diligence & Negotiation
开展技术尽调，就交易结构与条款展开谈判Technical due diligence, followed by deal structure and term negotiation
欢迎就任一管线展开交流Let's Talk About Any Pipeline
我们欢迎具备自身免疫、代谢或肿瘤领域商业化经验及全球化视野的合作方就任一管线展开交流。We welcome partners with commercialization experience in autoimmune, metabolic or oncology and a global outlook to start a conversation on any program.
与我们取得联系Get in Touch
无论是管线合作、投资咨询还是媒体垂询，我们都期待您的联系。Whether it's pipeline collaboration, investment inquiries or media requests, we look forward to hearing from you.
公司信息Company
苏州智和领生物医药科技有限公司Suzhou Zhiheling Biopharmaceutical Technology Co., Ltd.
Intelli-Link Therapeutics苏州智和领生物医药科技有限公司
数据摘要申请Teaser Request
希望进一步了解某项资产的分子设计、体内外数据或探讨合作可能？在右侧表单中说明关注的管线，或直接邮件联系 fulei@intlinkbio.com——我们将在签署 NDA 后提供非保密数据摘要（Non-CDA Teaser）与完整数据室访问。 Want to learn more about an asset's molecular design, in vitro/in vivo data, or explore collaboration? Mention the pipeline in the form, or email us directly at fulei@intlinkbio.com — after NDA execution we provide the Non-CDA Teaser and full Data Room access.
提交合作意向Submit Partnership Intent
带 * 为必填项。也可直接发送邮件至 fulei@intlinkbio.com。Fields marked * are required. You may also email fulei@intlinkbio.com directly.